Predictors of lithium response in bipolar disorder
暂无分享,去创建一个
[1] Lithium salts in the treatment of psychotic excitement. , 1949, The Medical journal of Australia.
[2] M. Schou,et al. THE TREATMENT OF MANIC PSYCHOSES BY THE ADMINISTRATION OF LITHIUM SALTS , 1954, Journal of neurology, neurosurgery, and psychiatry.
[3] P. Baastrup,et al. Lithium As a Prophylactic Agent: Its Effect Against Recurrent Depressions and Manic-Depressive Psychosis , 1967 .
[4] A. Amdisen,et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. , 1970, Lancet.
[5] R. Fieve,et al. Clinical factors in lithium carbonate prophylaxis failure. , 1974, Archives of general psychiatry.
[6] D. Sarantidis,et al. Predictors of lithium prophylaxis effectiveness. , 1981, Progress in neuro-psychopharmacology.
[7] J. Rapoport,et al. Lithium in children of lithium-responding parents , 1981, Psychiatry Research.
[8] Y. Y. Yang. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients , 1985, Acta psychiatrica Scandinavica.
[9] M. Maj,et al. Minimum Plasma Lithium Levels Required for Effective Prophylaxis in DSM III Bipolar Disorder: A Prospective Study , 1986, Pharmacopsychiatry.
[10] U. Hegerl,et al. Auditory Evoked Potentials and Response to Lithium Prophylaxis , 1987, Pharmacopsychiatry.
[11] B. Müller-Oerlinghausen,et al. Intensity dependence of auditory evoked potentials and clinical response to prophylactic lithium medication: A replication study , 1992, Psychiatry Research.
[12] T. Ōkuma. Effects of carbamazepine and lithium on affective disorders. , 1993, Neuropsychobiology.
[13] D. Slamon,et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.
[14] M. Alda,et al. Lithium response and genetics of affective disorders. , 1994, Journal of affective disorders.
[15] J. Barendregt,et al. Global burden of disease , 1997, The Lancet.
[16] Alan D. Lopez,et al. The global burden of disease, 1990–2020 , 1998, Nature Medicine.
[17] F. Engelsmann,et al. Predictors of Lithium Treatment Responsiveness in Bipolar Patients , 1998, Neuropsychobiology.
[18] J. Small,et al. Topographic EEG Studies of Mania , 1998, Clinical EEG.
[19] A. Serretti,et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. , 1999, Journal of psychiatric research.
[20] J. Small,et al. Clinical and quantitative EEG studies of mania. , 1999, Journal of affective disorders.
[21] N. Turan,et al. Predictors of lithium prophylaxis in bipolar patients. , 1999, Journal of affective disorders.
[22] J. Parrish,et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. , 1999, The American journal of psychiatry.
[23] M. Schou. The early European lithium studies. , 1999, The Australian and New Zealand journal of psychiatry.
[24] G. Moore,et al. Lithium-induced increase in human brain grey matter , 2000, The Lancet.
[25] Prediction of lithium response by 31P-MRS in bipolar disorder. , 2000, The international journal of neuropsychopharmacology.
[26] H. Akiskal,et al. Family history and symptom levels during treatment for bipolar I affective disorder , 2000, Biological Psychiatry.
[27] R. Reeves,et al. Does EEG Predict Response to Valproate Versus Lithium in Patients with Mania? , 2001, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[28] J. McCracken,et al. Decreased Anterior Cingulate Myo-inositol/Creatine Spectroscopy Resonance with Lithium Treatment in Children with Bipolar Disorder , 2001, Neuropsychopharmacology.
[29] G D Pearlson,et al. The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. , 2001, The American journal of psychiatry.
[30] A. Serretti,et al. Serotonin transporter gene associated with lithium prophylaxis in mood disorders , 2001, The Pharmacogenomics Journal.
[31] R. Baldessarini,et al. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. , 2001, The British journal of psychiatry : the journal of mental science.
[32] P. Sparén,et al. Excess mortality in bipolar and unipolar disorder in Sweden. , 2001, Archives of general psychiatry.
[33] A. Serretti. Lithium long-term treatment in mood disorders: clinical and genetic predictors. , 2002, Pharmacogenomics.
[34] M. Alda,et al. Is response to prophylactic lithium a familial trait? , 2002, The Journal of clinical psychiatry.
[35] N. Kato,et al. Possible relationship between electroencephalogram finding and lithium response in bipolar disorder , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[36] Mark A Frye,et al. Screening for bipolar disorder in the community. , 2003, The Journal of clinical psychiatry.
[37] S. Nanko,et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder , 2003, Nature Genetics.
[38] M. Alda,et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. , 2003, Bipolar disorders.
[39] P. Grof. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. , 2003, The Journal of clinical psychiatry.
[40] R. Baldessarini,et al. Rapid‐cycling bipolar disorder: effects of long‐term treatments , 2003, Acta psychiatrica Scandinavica.
[41] H. Möller,et al. Loudness Dependence of Primary Auditory-Cortex-Evoked Activity as Predictor of Therapeutic Outcome to Prophylactic Lithium Treatment in Affective Disorders - A Retrospective Study , 2004, Pharmacopsychiatry.
[42] K. Jamison,et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of psychiatry.
[43] N. Kleindienst,et al. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. , 2005, Bipolar disorders.
[44] Tadafumi Kato,et al. Lithium response and -116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder. , 2005, The international journal of neuropsychopharmacology.
[45] J. Hauser,et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. , 2005, Pharmacopsychiatry.
[46] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[47] D. Collier,et al. Association study of the INPP1, 5HTT, BDNF, AP-2β and GSK-3β GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder , 2006, Neuroscience Letters.
[48] R. Hashimoto,et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. , 2005, The international journal of neuropsychopharmacology.
[49] R. Hashimoto,et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. , 2006, Psychiatric genetics.
[50] N. Crossley,et al. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. , 2007, The Journal of clinical psychiatry.
[51] Aleksandra Suwalska,et al. Response to lithium prophylaxis: Interaction between serotonin transporter and BDNF genes , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[52] R. Kessler,et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. , 2007, Archives of general psychiatry.
[53] M. Alda,et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. , 2007, Journal of affective disorders.
[54] M. Alda,et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study , 2007, Psychopharmacology.
[55] M. Alda,et al. A Consecutive Series of Treated Affected Offspring of Parents with Bipolar Disorder: Is Response Associated with the Clinical Profile? , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[56] M. Alda,et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. , 2008, The Journal of clinical psychiatry.
[57] Agatha D. Lee,et al. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium , 2008, Neuroreport.
[58] R. Hashimoto,et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[59] J. Hauser,et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. , 2008, Pharmacogenomics.
[60] Chang Yoon Kim,et al. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders , 2009, Psychiatry Research.
[61] L. Backlund,et al. Identifying predictors for good lithium response – A retrospective analysis of 100 patients with bipolar disorder using a life-charting method , 2009, European Psychiatry.
[62] P. Grof,et al. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. , 2009, Bipolar disorders.
[63] S. Purcell,et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. , 2009, The American journal of psychiatry.
[64] J. Leon. Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders , 2009, Neuropsychopharmacology.
[65] W. Drevets,et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. , 2009, The Journal of clinical psychiatry.
[66] T. Schneider-Axmann,et al. Increased right amygdala volume in lithium‐treated patients with bipolar I disorder , 2010, Acta psychiatrica Scandinavica.
[67] P. Renshaw,et al. Lithium-Induced Gray Matter Volume Increase As a Neural Correlate of Treatment Response in Bipolar Disorder: A Longitudinal Brain Imaging Study , 2010, Neuropsychopharmacology.
[68] S. Cichon,et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. , 2010, Neuropsychobiology.
[69] R. Baldessarini,et al. Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials , 2011, Neuropsychopharmacology.
[70] J. Kelsoe,et al. The Pharmacogenetics of Lithium Response Depends upon Clinical Co-Morbidity , 2012, Molecular Diagnosis & Therapy.